October 7, 2021 09:32 AM EDTUpdated 11:06 AM

Bristol Myers' TYK2 drug bombs ulcerative colitis test, but hopes are still high with psoriasis filing on deck

Bristol Myers Squibb’s deucravacitinib, seeking to become the first TYK2 drug approved, flopped a key Phase II test in ulcerative colitis …

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Bris­tol My­er­s' TYK2 drug bombs ul­cer­a­tive col­i­tis test, but hopes are still high with pso­ri­a­sis fil­ing on deck